Desflurane and Anesthesia Recovery Period in Endonasal Endoscopic Pituitary Adenoma Resection

Pituitary Neoplasms Clinical Trial

Official title:

Effects of Desflurane on the Quality of Anesthesia Recovery Period in Patients Undergoing Endonasal Endoscopic Pituitary Adenoma Resection#a Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05088252
• Other study ID #: XUAN20211004
• Status: Completed
• Phase: N/A
• Start date: December 1, 2021
• Est. completion date: May 31, 2022

Study information

• Verified date: June 2023
• Source: Beijing Tiantan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Nasal packing is required after endoscopic pituitary adenoma resection. The patient can only breathe through the mouth. The blood and secretion in the nasal cavity may be inhaled into the trachea after the operation. GH-secreting pituitary adenoma causes pharyngeal soft tissue and tongue hypertrophy. These conditions increase the risk of respiratory obstruction and hypoxemia during anesthesia recovery. Propofol total intravenous anesthesia has a rapid effect and a low incidence of nausea and vomiting. Patients anesthetized with desflurane recover quickly is conducive to early recovery of respiratory function and orientation. This study intends to compare the effects of desflurane and propofol on the quality of anesthesia recovery period in patients undergoing endonasal endoscopic pituitary adenoma resection and to provide clinical evidence for the use of desflurane in neurosurgical anesthesia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: May 31, 2022
• Est. primary completion date: May 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 18-65 years;

• Elective endoscopic transsphenoidal resection of pituitary adenomas;

• ASA status I-III;

• Informed consent signed by patients.

Exclusion Criteria:

• emergency surgery;

• complicated with cerebrovascular disease;

• complicated with pulmonary disease, oxygen saturation below 95% without oxygen;

• expected to retain endotracheal intubation;

• preoperative disturbance of consciousness was not compatible with assessment;

• complicated with primary hypothyroidism;

• previous history of cervical surgery, burns, and radiotherapy;

• BMI >30kg/m2;

• invasive pituitary adenoma with Knosp grade 4.

Related Conditions & MeSH terms

• Adenoma
• Pituitary Diseases
• Pituitary Neoplasms

Intervention

Drug:
• Desflurane
After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and 0.05-0.3 µg/kg/min remifentanil.
• Propofol
After induction, anesthesia will be maintained with 4-6mg/kg/h propofol and 0.05- 0.3 µg/kg/min remifentanil.

Locations

Country	Name	City	State
China	Ruquan Han	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time required of the Aldrete score reached 9 points after drug withdrawal.		immediately after the surgery